Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS (SCYX)
NASDAQ:SCYX
Top Page
SCYNEXIS
(NASDAQ:SCYX)
47Neutral
Positive Factors
Product Efficacy
The Phase 3 FURI data for Ibrexafungerp showed a 60.9% treatment success rate, which is consistent with interim data and a very good result in this setting.
Strategic Partnerships
The drug Ibrexafungerp has been licensed to GlaxoSmithKline for commercialization.
Negative Factors
Market Competition
Scynexis is advancing towards the relaunch of the P3 MARIO study in invasive candidiasis, expected in 1Q25, with active manufacturing efforts supporting this.
SCYNEXIS (SCYX) vs. S&P 500 (SPY)
Market Cap
$34.20M
Dividend YieldN/A
Average Volume (3M)155.94K
Price to Earnings (P/E)―
Beta (1Y)2.50
Revenue Growth-93.70%
EPS Growth-163.86%
CountryUS
Employees29
SectorHealthcare
Sector Strength78
IndustryPharmaceuticals
Share Statistics
EPS (TTM)-0.91
Shares Outstanding37,948,990
10 Day Avg. Volume136,167
30 Day Avg. Volume155,944
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.99
Price to Cash Flow (P/CF)11.20
P/FCF Ratio11.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.00Price Target Upside365.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
SCYNEXIS Business Overview & Revenue Model
Company DescriptionSCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
How the Company Makes MoneySCYNEXIS generates revenue primarily through the development and commercialization of its antifungal therapies, particularly ibrexafungerp. The company earns money by selling its products to healthcare providers, hospitals, and pharmacies. SCYNEXIS may also engage in licensing agreements with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on product sales. Additionally, the company may receive funding from research grants or collaborations with other organizations in the biotechnology and pharmaceutical industries.
SCYNEXIS Financial Statement Overview
Summary
SCYNEXIS faces financial challenges with fluctuating revenues, persistent losses, and negative cash flows. However, recent improvements in stockholders' equity and operating cash flow suggest potential recovery opportunities.Income Statement
SCYNEXIS has demonstrated volatile revenue patterns, with significant fluctuations over the years. The TTM revenue has considerably decreased compared to the previous year. Negative gross profit margins and a consistent pattern of net losses highlight ongoing operational challenges. However, the company showed some positive revenue growth in 2023, indicating potential recovery.45
Neutral
Balance Sheet
The balance sheet indicates a moderate debt-to-equity ratio and substantial cash reserves relative to the company's debt, suggesting a conservative approach to leverage. However, the persistent negative equity in earlier years raises concerns about financial stability. Recent improvements in stockholders' equity are promising, signaling a potential strengthening of the company's financial position.50
Neutral
Cash Flow
SCYNEXIS's cash flow statements reveal challenges with generating positive free cash flow, with ongoing negative free cash flow in the TTM. The operating cash flow has improved significantly in 2023, but sustainability remains uncertain. High operating cash flow to net income ratio in 2023 indicates efficient cash generation relative to net income.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 8.57M | 140.14M | 5.09M | 13.16M | 0.00 | 121.00K | Gross Profit |
| -6.25M | 124.52M | 4.46M | 12.85M | -303.00K | 121.00K | EBIT |
| -52.13M | 72.67M | -85.76M | -60.83M | -51.15M | -48.92M | EBITDA |
| -44.91M | 73.48M | -59.91M | -31.41M | -51.15M | -51.27M | Net Income Common Stockholders |
| -36.44M | 67.04M | -62.81M | -32.87M | -55.19M | -55.23M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 44.16M | 74.36M | 73.50M | 104.48M | 93.04M | 48.41M | Total Assets |
| 53.17M | 128.41M | 87.81M | 119.84M | 102.54M | 57.15M | Total Debt |
| 15.08M | 15.08M | 48.60M | 43.63M | 19.84M | 14.88M | Net Debt |
| 3.64M | -18.97M | 2.78M | -60.86M | -73.20M | -27.04M | Total Liabilities |
| 21.95M | 55.45M | 84.58M | 78.58M | 79.78M | 44.26M | Stockholders Equity |
| 31.23M | 72.96M | 3.23M | 41.26M | 22.76M | 12.89M |
| Cash Flow | Free Cash Flow | ||||
| -21.84M | 60.16M | -79.89M | -55.73M | -49.36M | -38.12M | Operating Cash Flow |
| -21.84M | 60.16M | -79.88M | -54.56M | -49.35M | -38.12M | Investing Cash Flow |
| 6.62M | -34.88M | -27.39M | -1.17M | 6.47M | 26.24M | Financing Cash Flow |
| -119.00K | -36.72M | 48.60M | 67.12M | 94.00M | 42.30M |
SCYNEXIS Technical Analysis
Negative
0.86
Price Trends
1.10
Negative
1.19
Negative
1.51
Negative
Market Momentum
-0.05
Positive
35.60
Neutral
14.45
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Negative. The current price of 0.86 is below the 20-day moving average (MA) of 1.02, below the 50-day MA of 1.10, and below the 200-day MA of 1.51, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 35.60 is Neutral, neither overbought nor oversold. The STOCH value of 14.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCYX.
SCYNEXIS Risk Analysis
SCYNEXIS disclosed 47 risk factors in its most recent earnings report. SCYNEXIS reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SCYNEXIS Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $96.52M | ― | -162.87% | ― | -100.00% | 35.07% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
47 Neutral | $34.20M | ― | -48.42% | ― | -93.70% | -163.86% | |
44 Neutral | $36.51M | ― | -137.40% | ― | ― | 37.42% | |
44 Neutral | $23.43M | ― | -221.25% | ― | -59.08% | 18.99% | |
42 Neutral | $78.50M | ― | -46.28% | ― | -33.00% | 54.91% | |
39 Underperform | $16.20M | ― | -25.70% | ― | ― | 86.44% |
* Healthcare Sector Average
Performance Comparison
SCYX
SCYNEXIS
0.86
-0.64
-42.67%
CARA
Cara Therapeutics
5.06
-4.38
-46.40%
XTLB
XTL Biopharmaceuticals Ltd. Sponsored ADR
1.24
0.36
40.91%
VTGN
VistaGen Therapeutics
2.72
-1.20
-30.61%
FBRX
Forte Biosciences
6.00
-10.22
-63.01%
MIST
Milestone Pharmaceuticals
2.03
0.61
42.96%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.